A Single Blind, Randomised, Multi-centre, Active Controlled, Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Cefepime
- Indications Urinary tract infections
- Focus Adverse reactions
- Sponsors AstraZeneca; Pfizer
- 10 Oct 2017 Planned End Date changed from 2 Oct 2017 to 2 Nov 2017.
- 10 Oct 2017 Planned primary completion date changed from 2 Oct 2017 to 2 Nov 2017.
- 21 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.